2nd Engrossment - 89th Legislature (2015 - 2016) Posted on 03/23/2015 04:00pm
Version List Authors and Status
A bill for an act
relating to health; making changes to the Minnesota prescription monitoring
program; amending Minnesota Statutes 2014, section 152.126, subdivisions 1, 3,
5, 6; repealing Laws 2014, chapter 286, article 7, section 4.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
Minnesota Statutes 2014, section 152.126, subdivision 1, is amended to read:
(a) For purposes of this section, the terms defined in
this subdivision have the meanings given.
(b) "Board" means the Minnesota State Board of Pharmacy established under
(c) "Controlled substances" means those substances listed in section 152.02,
subdivisions 3 to 6, and those substances defined by the board pursuant to section 152.02,
subdivisions 7, 8, and 12. For the purposes of this section, controlled substances includes
deleted text begintramadol anddeleted text end butalbitalnew text beginnew text end.
(d) "Dispense" or "dispensing" has the meaning given in section 151.01, subdivision
30. Dispensing does not include the direct administering of a controlled substance to a
patient by a licensed health care professional.
(e) "Dispenser" means a person authorized by law to dispense a controlled substance,
pursuant to a valid prescription. For the purposes of this section, a dispenser does not
include a licensed hospital pharmacy that distributes controlled substances for inpatient
hospital care or a veterinarian who is dispensing prescriptions under section 156.18.
(f) "Prescriber" means a licensed health care professional who is authorized to
prescribe a controlled substance under section 152.12, subdivision 1 or 2.
(g) "Prescription" has the meaning given in section 151.01, subdivision deleted text begin16deleted text end
new text beginnew text end.
Minnesota Statutes 2014, section 152.126, subdivision 3, is amended to read:
(a) The board
shall appoint an advisory task force consisting of at least one representative of:
(1) the Department of Health;
(2) the Department of Human Services;
(3) each health-related licensing board that licenses prescribers;
(4) a professional medical association, which may include an association of pain
management and chemical dependency specialists;
(5) a professional pharmacy association;
(6) a professional nursing association;
(7) a professional dental association;
(8) a consumer privacy or security advocate;
(9) a consumer or patient rights organization; and
(10) an association of medical examiners and coroners.
(b) The advisory task force shall advise the board on the development and operation
of the prescription monitoring program, including, but not limited to:
(1) technical standards for electronic prescription drug reporting;
(2) proper analysis and interpretation of prescription monitoring data;
(3) an evaluation process for the program; and
(4) criteria for the unsolicited provision of prescription monitoring data by the
board to prescribers and dispensers.
(c) The task force is governed by section 15.059. new text beginnew text endthe task force shall not expire.
Minnesota Statutes 2014, section 152.126, subdivision 5, is amended to read:
(a) The board shall develop and maintain a database
of the data reported under subdivision 4. The board shall maintain data that could identify
an individual prescriber or dispenser in encrypted form. Except as otherwise allowed
under subdivision 6, the database may be used by permissible users identified under
subdivision 6 for the identification of:
(1) individuals receiving prescriptions for controlled substances from prescribers
who subsequently obtain controlled substances from dispensers in quantities or with a
frequency inconsistent with generally recognized standards of use for those controlled
substances, including standards accepted by national and international pain management
(2) individuals presenting forged or otherwise false or altered prescriptions for
controlled substances to dispensers.
(b) No permissible user identified under subdivision 6 may access the database
for the sole purpose of identifying prescribers of controlled substances for unusual or
excessive prescribing patterns without a valid search warrant or court order.
(c) No personnel of a state or federal occupational licensing board or agency may
access the database for the purpose of obtaining information to be used to initiate deleted text beginor
substantiatedeleted text end a disciplinary action against a prescriber.
(d) Data reported under subdivision 4 shall be made available to permissible users for
a 12-month period beginning the day the data was received and ending 12 months from the
last day of the month in which the data was received, except that permissible users defined
in subdivision 6, paragraph (b), clauses (6) and (7), may use all data collected under this
section for the purposes of administering, operating, and maintaining the prescription
monitoring program and conducting trend analyses and other studies necessary to evaluate
the effectiveness of the program. deleted text beginData retained beyond 24 months must be de-identified.
deleted text end
(e) The board shall not retain data reported under subdivision 4 for a period longer
than four years from the date the data was received.
Minnesota Statutes 2014, section 152.126, subdivision 6, is amended to read:
(a) Except as indicated in this
subdivision, the data submitted to the board under subdivision 4 is private data on
individuals as defined in section 13.02, subdivision 12, and not subject to public disclosure.
(b) Except as specified in subdivision 5, the following persons shall be considered
permissible users and may access the data submitted under subdivision 4 in the same or
similar manner, and for the same or similar purposes, as those persons who are authorized
to access similar private data on individuals under federal and state law:
(1) a prescriber or an agent or employee of the prescriber to whom the prescriber has
delegated the task of accessing the data, to the extent the information relates specifically to
a current patient, to whom the prescriber is:
(i) prescribing or considering prescribing any controlled substance;
(ii) providing emergency medical treatment for which access to the data may be
(iii) providing other medical treatment for which access to the data may be necessary
and the patient has consented to access to the submitted data, and with the provision that
the prescriber remains responsible for the use or misuse of data accessed by a delegated
agent or employee;
(2) a dispenser or an agent or employee of the dispenser to whom the dispenser has
delegated the task of accessing the data, to the extent the information relates specifically
to a current patient to whom that dispenser is dispensing or considering dispensing any
controlled substance and with the provision that the dispenser remains responsible for the
use or misuse of data accessed by a delegated agent or employee;
(3) a licensed pharmacist who is providing pharmaceutical care for which access
to the data may be necessary to the extent that the information relates specifically to a
current patient for whom the pharmacist is providing pharmaceutical care if the patient
has consented to access to the submitted datanew text beginnew text end;
(4) an individual who is the recipient of a controlled substance prescription for
which data was submitted under subdivision 4, or a guardian of the individual, parent or
guardian of a minor, or health care agent of the individual acting under a health care
directive under chapter 145C;
(5) personnel new text beginnew text endof deleted text beginthedeleted text end
new text beginnew text end board deleted text beginspecificallydeleted text end
new text beginnew text end
assigned to conduct a bona fide investigation of a new text beginnew text endspecific licenseenew text beginnew text end;
(6) personnel of the board engaged in the collection, review, and analysis
of controlled substance prescription information as part of the assigned duties and
responsibilities under this section;
(7) authorized personnel of a vendor under contract with the state of Minnesota who
are engaged in the design, implementation, operation, and maintenance of the prescription
monitoring program as part of the assigned duties and responsibilities of their employment,
provided that access to data is limited to the minimum amount necessary to carry out such
duties and responsibilities, and subject to the requirement of de-identification and time
limit on retention of data specified in subdivision 5, paragraphs (d) and (e);
(8) federal, state, and local law enforcement authorities acting pursuant to a valid
(9) personnel of the Minnesota health care programs assigned to use the data
collected under this section to identify and manage recipients whose usage of controlled
substances may warrant restriction to a single primary care provider, a single outpatient
pharmacy, and a single hospital;
(10) personnel of the Department of Human Services assigned to access the data
pursuant to paragraph (h); deleted text beginand
deleted text end
(11) personnel of the health professionals services program established under section
214.31, to the extent that the information relates specifically to an individual who is
currently enrolled in and being monitored by the program, and the individual consents to
access to that information. The health professionals services program personnel shall not
provide this data to a health-related licensing board or the Emergency Medical Services
Regulatory Board, except as permitted under section 214.33, subdivision 3.
For purposes of clause (4), access by an individual includes persons in the definition
of an individual under section 13.02 deleted text begin.deleted text end new text beginnew text end
new text beginnew text end
(c) deleted text beginA permissible userdeleted text end
new text beginnew text end identified in paragraph (b), clauses
(1), (2), (3), (6), (7), (9), and (10), may directly access the data electronically. new text beginnew text end If the data is directly accessed
electronically, the permissible user shall implement and maintain a comprehensive
information security program that contains administrative, technical, and physical
safeguards that are appropriate to the user's size and complexity, and the sensitivity of the
personal information obtained. The permissible user shall identify reasonably foreseeable
internal and external risks to the security, confidentiality, and integrity of personal
information that could result in the unauthorized disclosure, misuse, or other compromise
of the information and assess the sufficiency of any safeguards in place to control the risks.
(d) The board shall not release data submitted under subdivision 4 unless it
is provided with evidence, satisfactory to the board, that the person requesting the
information is entitled to receive the data.
(e) The board shall maintain a log of all persons who access the data for a period of
at least three years and shall ensure that any permissible user complies with paragraph (c)
prior to attaining direct access to the data.
(f) Section 13.05, subdivision 6, shall apply to any contract the board enters into
pursuant to subdivision 2. A vendor shall not use data collected under this section for
any purpose not specified in this section.
(g) The board may participate in an interstate prescription monitoring program data
exchange system provided that permissible users in other states have access to the data
only as allowed under this section, and that section 13.05, subdivision 6, applies to any
contract or memorandum of understanding that the board enters into under this paragraph.
The board shall report to the chairs and ranking minority members of the senate and house
of representatives committees with jurisdiction over health and human services policy and
finance on the interstate prescription monitoring program by January 5, 2016.
(h) With available appropriations, the commissioner of human services shall
establish and implement a system through which the Department of Human Services shall
routinely access the data for the purpose of determining whether any client enrolled in
an opioid treatment program licensed according to chapter 245A has been prescribed or
dispensed a controlled substance in addition to that administered or dispensed by the
opioid treatment program. When the commissioner determines there have been multiple
prescribers or multiple prescriptions of controlled substances, the commissioner shall:
(1) inform the medical director of the opioid treatment program only that the
commissioner determined the existence of multiple prescribers or multiple prescriptions of
controlled substances; and
(2) direct the medical director of the opioid treatment program to access the data
directly, review the effect of the multiple prescribers or multiple prescriptions, and
document the review.
If determined necessary, the commissioner of human services shall seek a federal waiver
of, or exception to, any applicable provision of Code of Federal Regulations, title 42,
section 2.34, paragraph (c), prior to implementing this paragraph.
(i) The board shall review the data submitted under subdivision 4 on at least a
quarterly basis and shall establish criteria, in consultation with the advisory task force,
for referring information about a patient to prescribers and dispensers who prescribed or
dispensed the prescriptions in question if the criteria are met. The board shall report
to the chairs and ranking minority members of the senate and house of representatives
committees with jurisdiction over health and human services policy and finance on the
criteria established under this paragraph and the review process by January 5, 2016. This
paragraph expires August 1, 2016.
new text beginnew text end new text beginnew text end